2025
Validation and refinement of Society of Immunotherapy of Cancer (SITC) definitions for PD-(L)1 resistance: An analysis of more than 1,300 participants from SWOG.
Othus M, Kurzrock R, Patel S, Chae Y, Patel S, Sosman J, Snyder Charen A, Rizvi N, LaVallee T, Felquate D, Burton E, Futreal P, Sullivan R, Kluger H, Tawbi H. Validation and refinement of Society of Immunotherapy of Cancer (SITC) definitions for PD-(L)1 resistance: An analysis of more than 1,300 participants from SWOG. Journal Of Clinical Oncology 2025, 43: 2656-2656. DOI: 10.1200/jco.2025.43.16_suppl.2656.Peer-Reviewed Original ResearchOverall survivalMartingale residual plotsAdjuvant settingPD-(L)1Shorter OSNo significant differencePrimary resistanceAssociated with significantly shorter OSHazard ratioHigh-risk resected stagePD-(L)1 inhibitorsImmunotherapy of cancerSignificant differenceConfidence intervalsCox regression modelsClinical trial interpretationAdjuvant cohortAdjuvant pembrolizumabImmunotherapy resistanceLate recurrenceResected stageEarly recurrenceSWOG trialsIO agentsPatient cohort
2024
Late recurrence of completely resected stage I to IIIA lung adenocarcinoma
Fick C, Dunne E, Toumbacaris N, Tan K, Mastrogiacomo B, Park B, Adusumilli P, Molena D, Gray K, Sihag S, Huang J, Bott M, Rocco G, Isbell J, Jones D. Late recurrence of completely resected stage I to IIIA lung adenocarcinoma. Journal Of Thoracic And Cardiovascular Surgery 2024, 169: 445-453.e3. PMID: 38950771, PMCID: PMC11682191, DOI: 10.1016/j.jtcvs.2024.06.026.Peer-Reviewed Original ResearchAggressive pathological featuresLate recurrenceLung adenocarcinomaFollow-upPathological featuresAssociated with late recurrenceElevated risk of recurrenceFactors associated with late recurrenceRetrospective analysis of patientsRecurrence of lung adenocarcinomaHistory of lung cancerStage IIIA diseaseTime of resectionRisk of recurrenceAnalysis of patientsGenomic mutationsNeoadjuvant therapyIIIA diseaseEarly recurrenceClinicopathological variablesLogistic regression modelsRetrospective analysisLung cancerRecurrencePatients
2023
Immuno-chemotherapy as single treatment modality for larynx preservation (ICoLP): Co-primary endpoints and safety results.
Ferrarotto R, Johnson F, Hutcheson K, Sui D, Johnson J, Ebersole B, Mott F, Lewis C, Bonini F, Hoff C, Mitani Y, Cortez M, Bell D, El-Naggar A, Gunn G, Fuller C, Myers J, Lee J, Rosenthal D, Diaz E. Immuno-chemotherapy as single treatment modality for larynx preservation (ICoLP): Co-primary endpoints and safety results. Journal Of Clinical Oncology 2023, 41: 6008-6008. DOI: 10.1200/jco.2023.41.16_suppl.6008.Peer-Reviewed Original ResearchTreatment-related adverse eventsPathologic complete responseLarynx squamous cell carcinomaCo-primary endpointsEarly recurrenceCommon treatment-related adverse eventsStage IIDisease control rateLaryngeal preservation rateSolitary lung metastasisRelapse-free survivalSquamous cell carcinomaLoss of insuranceSingle treatment modalityAUC 6Eligible ptsEvaluable patientsImmuno-chemotherapyLarynx biopsiesDefinitive radiotherapyEfficacy endpointPrimary endpointRECIST 1.1Secondary endpointsAdverse eventsMonitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers
Bellone S, McNamara B, Mutlu L, Demirkiran C, Hartwich T, Harold J, Yang-Hartwich Y, Siegel E, Santin A. Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers. International Journal Of Molecular Sciences 2023, 24: 8873. PMID: 37240216, PMCID: PMC10219151, DOI: 10.3390/ijms24108873.Peer-Reviewed Original ResearchConceptsUterine serous carcinomaCS patientsEarly recurrenceDroplet digital polymerase chain reactionCA 125Serous carcinomaCtDNA testingTime of surgeryTime of recurrenceReliable tumor biomarkersTumour DNA biomarkersCarcinosarcoma patientsUSC patientsRecurrent diseaseOccult diseaseOverall survivalEndometrial cancerAggressive variantInitial treatmentRecurrent tumorsResidual tumorClinical findingsTreatment courseTreatment trialsPIK3CA mutationsPost-operative PET/CT improves the detection of early recurrence of squamous cell carcinomas of the oral cavity
Yu Y, Schöder H, Zakeri K, Chen L, Kang J, McBride S, Tsai C, Gelblum D, Boyle J, Cracchiolo J, Cohen M, Singh B, Ganly I, Patel S, Michel L, Dunn L, Sherman E, Pfister D, Wong R, Riaz N, Lee N. Post-operative PET/CT improves the detection of early recurrence of squamous cell carcinomas of the oral cavity. Oral Oncology 2023, 141: 106400. PMID: 37099979, PMCID: PMC10631462, DOI: 10.1016/j.oraloncology.2023.106400.Peer-Reviewed Original ResearchConceptsOral squamous cell carcinomaIntermediate-risk featuresPET/CTHigh-risk featuresPost-operative radiationSquamous cell carcinomaEarly recurrenceRisk featuresSurgical marginsCell carcinomaPET/CT planningAddition of chemotherapyClose surgical marginsDisease-free survivalPositive surgical marginsRecords of patientsPositron emission tomographyTreatment intensificationBaseline characteristicsNode positivityLymphovascular invasionOverall survivalPT3-4Perineural invasionTumor thicknessRecurrence risk in symptomatic intracranial stenosis treated medically in the real world
Yaghi S, Shu L, Goldstein E, Chang A, Kala N, Stretz C, Burton T, Perelstein E, Furie K, Jayaraman M, Torabi R, Moldovan K, de Havenon A, Khatri P, Gebregziabher M, Liebeskind D, Prabhakaran S. Recurrence risk in symptomatic intracranial stenosis treated medically in the real world. Journal Of Stroke And Cerebrovascular Diseases 2023, 32: 107086. PMID: 37030126, DOI: 10.1016/j.jstrokecerebrovasdis.2023.107086.Peer-Reviewed Original ResearchConceptsIntracranial atherosclerotic stenosisSymptomatic intracranial atherosclerotic stenosisClinical trialsRecurrence riskRecurrent strokeInclusion criteriaReal-world settingMaximal medical treatmentRecurrent stroke rateDual antiplatelet therapyAcute ischemic strokeReal-world cohortSymptomatic intracranial stenosisPharmacological treatment strategiesCox regression modelMeeting inclusion criteriaLow event ratesAntiplatelet therapyStroke RegistryIschemic eventsIschemic strokeWorld CohortHospitalized patientsEarly recurrenceIntracranial stenosisASO Visual Abstract: PI3K Pathway Alterations in Peritoneal Metastases are Associated with Earlier Recurrence for Patients with Colorectal Cancer Undergoing Optimal Cytoreductive Surgery
Peerenboom R, Dhiman A, Witmer H, Spurr L, Polite B, Eng O, Shergill A, Turaga K. ASO Visual Abstract: PI3K Pathway Alterations in Peritoneal Metastases are Associated with Earlier Recurrence for Patients with Colorectal Cancer Undergoing Optimal Cytoreductive Surgery. Annals Of Surgical Oncology 2023, 30: 3123-3124. DOI: 10.1245/s10434-022-12854-w.Peer-Reviewed Original ResearchPI3K Pathway Alterations in Peritoneal Metastases are Associated with Earlier Recurrence in Patients with Colorectal Cancer Undergoing Optimal Cytoreductive Surgery
Peerenboom R, Dhiman A, Witmer H, Spurr L, Polite B, Eng O, Shergill A, Turaga K. PI3K Pathway Alterations in Peritoneal Metastases are Associated with Earlier Recurrence in Patients with Colorectal Cancer Undergoing Optimal Cytoreductive Surgery. Annals Of Surgical Oncology 2023, 30: 3114-3122. PMID: 36637640, DOI: 10.1245/s10434-022-12784-7.Peer-Reviewed Original ResearchConceptsOptimal cytoreductive surgeryPI3K pathway alterationsRecurrence-free survivalAssociated with early recurrenceCytoreductive surgeryCRC-PMPeritoneal metastasisRTK-RASEarly recurrenceImpact of tumor biologyReduced risk of recurrenceCRC-PM patientsMonths to recurrenceBiologically heterogeneous diseaseRisk of recurrenceCox proportional hazards modelsRTK-RAS pathwayClinically meaningful impactPI3KFrequency of alterationsSignaling pathwayProportional hazards modelCytoreduced patientsOptimal cytoreductionConclusionsIn patients
2022
Tiliroside suppresses triple-negative breast cancer as a multifunctional CAXII inhibitor
Han R, Yang H, Ling C, Lu L. Tiliroside suppresses triple-negative breast cancer as a multifunctional CAXII inhibitor. Cancer Cell International 2022, 22: 368. PMID: 36424626, PMCID: PMC9685933, DOI: 10.1186/s12935-022-02786-6.Peer-Reviewed Original ResearchTriple-negative breast cancerBreast cancerTNBC cellsBreast cancer treatmentNegative breast cancerCaspase-3 activity analysisExpression levelsSpheroid formation assayFurther RT-PCRTNBC patientsTumor burdenEarly recurrencePoor prognosisAggressive subtypeChemotherapy responseAlternative therapiesPreclinical studiesTNBC progressionMouse modelTherapeutic implicationsPreclinical experimentsSurvival rateTherapeutic useClinic practiceLevel assaysIntermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group
Tan W, Steinberg G, Witjes J, Li R, Shariat S, Roupret M, Babjuk M, Bivalacqua T, Psutka S, Williams S, Cookson M, Palou J, Kamat A. Intermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. European Urology Oncology 2022, 5: 505-516. PMID: 35718695, DOI: 10.1016/j.euo.2022.05.005.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerInternational Bladder Cancer GroupBladder cancer groupManagement of patientsIntermediate-riskIntravesical treatmentCancer groupRisk factorsClinical trialsIntravesical chemotherapyMultifocal tumorsEarly recurrenceTumor sizeBladder cancerFrequent recurrenceHeterogeneous diseaseGrading systemCarcinoma in situStage of tumorPostoperative intravesical chemotherapyRandomized clinical trialsMaintenance BCGComparison of outcomesRecurrent diseaseClinical practice guidance
2021
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer
Symmans WF, Yau C, Chen YY, Balassanian R, Klein ME, Pusztai L, Nanda R, Parker BA, Datnow B, Krings G, Wei S, Feldman MD, Duan X, Chen B, Sattar H, Khazai L, Zeck JC, Sams S, Mhawech-Fauceglia P, Rendi M, Sahoo S, Ocal IT, Fan F, LeBeau LG, Vinh T, Troxell ML, Chien AJ, Wallace AM, Forero-Torres A, Ellis E, Albain KS, Murthy RK, Boughey JC, Liu MC, Haley BB, Elias AD, Clark AS, Kemmer K, Isaacs C, Lang JE, Han HS, Edmiston K, Viscusi RK, Northfelt DW, Khan QJ, Leyland-Jones B, Venters SJ, Shad S, Matthews JB, Asare SM, Buxton M, Asare AL, Rugo HS, Schwab RB, Helsten T, Hylton NM, van ’t Veer L, Perlmutter J, DeMichele AM, Yee D, Berry DA, Esserman LJ. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer. JAMA Oncology 2021, 7: 1654-1663. PMID: 34529000, PMCID: PMC8446908, DOI: 10.1001/jamaoncol.2021.3690.Peer-Reviewed Original ResearchConceptsEvent-free survivalPathologic complete responseResidual cancer burdenInvestigational agentsInvestigational treatmentBreast cancerInterpretation of efficacyNeoadjuvant treatmentCancer burdenClinical trialsImproved event-free survivalNeoadjuvant breast cancer trialsStage 2/3 breast cancerHigh-risk breast cancerHormone receptorsI-SPY2 trialSecondary end pointsBreast cancer trialsEffective neoadjuvant treatmentI-SPY2Neoadjuvant paclitaxelNeoadjuvant trialsComplete responseEarly recurrencePrognostic significancePostoperative PET/CT for detection of early recurrence (ER) after surgery for squamous cell carcinomas (SCC) of the oral cavity (OC).
Yu Y, Schöder H, Kang J, McBride S, Tsai C, Chen L, Zakeri K, Gelblum D, Boyle J, Cracchiolo J, Cohen M, Singh B, Ganly I, Patel S, Michel L, Dunn L, Pfister D, Wong R, Riaz N, Lee N. Postoperative PET/CT for detection of early recurrence (ER) after surgery for squamous cell carcinomas (SCC) of the oral cavity (OC). Journal Of Clinical Oncology 2021, 39: 6060-6060. DOI: 10.1200/jco.2021.39.15_suppl.6060.Peer-Reviewed Original ResearchPostoperative PET/CTIntermediate risk factorsSquamous cell carcinomaHigh-risk factorsPET/CTPT3-4 diseasePositive surgical marginsEarly recurrenceSurgical marginsExtranodal extensionLymphovascular invasionPerineural invasionRisk factorsOral cavityPostoperative radiotherapyOverall survivalPostoperative radiationPET/CT planningDistant metastasis-free survivalImproved disease-free survivalClinicopathologic risk factorsClose surgical marginsDisease-free survivalSalvage therapyDistant recurrenceIschaemic stroke on anticoagulation therapy and early recurrence in acute cardioembolic stroke: the IAC study
Yaghi S, Henninger N, Giles JA, Guerrero C, Mistry E, Liberman AL, Asad D, Liu A, Nagy M, Kaushal A, Azher I, Mac Grory B, Fakhri H, Espaillat K, Pasupuleti H, Martin H, Tan J, Veerasamy M, Esenwa C, Cheng N, Moncrieffe K, Moeini-Naghani I, Siddu M, Scher E, Trivedi T, Furie KL, Keyrouz SG, Nouh A, de Havenon A, Khan M, Smith EE, Gurol ME. Ischaemic stroke on anticoagulation therapy and early recurrence in acute cardioembolic stroke: the IAC study. Journal Of Neurology Neurosurgery & Psychiatry 2021, 92: 1062-1067. PMID: 33903185, PMCID: PMC8448925, DOI: 10.1136/jnnp-2021-326166.Peer-Reviewed Original ResearchConceptsRecurrent ischemic eventsSymptomatic intracranial hemorrhageIschemic strokeIschemic eventsAtrial fibrillationAnticoagulation therapyAcute cardioembolic strokeAnticoagulation-naïve patientsInitiation of anticoagulationStroke prevention measuresComprehensive stroke centerIschemic stroke patientsAcute ischemic strokeCox regression analysisSecondary prevention strategiesCox hazard modelSICH riskAnticoagulant therapyAnticoagulation statusStroke centersCardioembolic strokeAF patientsConsecutive patientsEarly recurrenceIntracranial hemorrhage
2020
Anticoagulation Type and Early Recurrence in Cardioembolic Stroke
Yaghi S, Mistry E, Liberman AL, Giles J, Asad SD, Liu A, Nagy M, Kaushal A, Azher I, Mac Grory B, Fakhri H, Brown Espaillat K, Pasupuleti H, Martin H, Tan J, Veerasamy M, Esenwa C, Cheng N, Moncrieffe K, Moeini-Naghani I, Siddu M, Scher E, Trivedi T, Lord A, Furie K, Keyrouz S, Nouh A, Leon Guerrero CR, de Havenon A, Khan M, Henninger N. Anticoagulation Type and Early Recurrence in Cardioembolic Stroke. Stroke 2020, 51: 2724-2732. PMID: 32757753, PMCID: PMC7484360, DOI: 10.1161/strokeaha.120.028867.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnticoagulantsAtrial FibrillationBrain IschemiaEmbolismFemaleHeart DiseasesHeparin, Low-Molecular-WeightHumansIncidenceIntracranial HemorrhagesMaleMiddle AgedNeuroimagingRecurrenceRegistriesRetrospective StudiesRisk AssessmentStrokeTreatment OutcomeUnited StatesWarfarinConceptsSymptomatic intracranial hemorrhageRecurrent ischemic eventsLow molecular weight heparinAcute ischemic strokeMolecular weight heparinIschemic eventsIntracranial hemorrhageIschemic strokeAtrial fibrillationAnalysis inclusion criteriaEarly recurrenceWeight heparinInclusion criteriaSeparate Cox regression analysesComprehensive stroke centerLarge prospective studiesOral anticoagulant therapyCox regression analysisCox regression modelAnticoagulation typeDOAC treatmentStroke RegistryAnticoagulant therapyCardioembolic strokeStroke centersBorder-zone Infarcts Predict Early Recurrence in Patients with Large Artery Atherosclerotic Subtype Despite Medical Treatment (2753)
Kvernland A, Prabhakaran S, Khatri P, de Havenon A, Yeatts S, Scher E, Torres J, Ishida K, Frontera J, Lord A, Liebeskind D, Yaghi S. Border-zone Infarcts Predict Early Recurrence in Patients with Large Artery Atherosclerotic Subtype Despite Medical Treatment (2753). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.2753.Peer-Reviewed Original Research
2019
Polysomy is associated with poor outcome in 1p/19q codeleted oligodendroglial tumors
Chen H, Thomas C, Munoz FA, Alexandrescu S, Horbinski CM, Olar A, McGuone D, Camelo-Piragua S, Wang L, Pentsova E, Phillips J, Aldape K, Chen W, Iafrate AJ, S AS, Zagzag D, Golfinos JG, Placantonakis DG, Rosenblum M, Ohman-Strickland P, Hameed M, Snuderl M. Polysomy is associated with poor outcome in 1p/19q codeleted oligodendroglial tumors. Neuro-Oncology 2019, 21: 1164-1174. PMID: 31140557, PMCID: PMC7571489, DOI: 10.1093/neuonc/noz098.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAneuploidyBrain NeoplasmsChemotherapy, AdjuvantChildChromosomal InstabilityChromosome DeletionChromosomes, Human, Pair 1Chromosomes, Human, Pair 19FemaleHumansIn Situ Hybridization, FluorescenceIsocitrate DehydrogenaseMaleMiddle AgedNeoadjuvant TherapyNeurosurgical ProceduresOligodendrogliomaPrognosisProgression-Free SurvivalRadiotherapy, AdjuvantSurvival RateYoung AdultConceptsProgression-free survivalOverall survivalOligodendroglial tumorsPrognostic significanceBetter progression-free survivalLonger progression-free survivalPolysomic cellsCodeletion of 1p/19qPresence of polysomyEarly recurrenceShorter survivalPoor outcomeEarly progressionPatientsTumorsSurvivalPolysomySitu hybridizationCodeletionChromosomal instabilityCellsGroupPrior studiesStatusRecurrence
2016
MPTH-34. THE PROGNOSTIC VALUE OF POLYSOMY IN OLIGODENDROGLIAL TUMORS
Chen H, Thomas C, Munoz F, Alexandrescu S, Horbinski C, Olar A, McGuone D, Camelo-Piragua S, Wang L, Pentsova E, Phillips J, Aldape K, Iafrate A, Golfinos J, Chi A, Zagzag D, Rosenblum M, Ohman-Strickland P, Hameed M, Snuderl M. MPTH-34. THE PROGNOSTIC VALUE OF POLYSOMY IN OLIGODENDROGLIAL TUMORS. Neuro-Oncology 2016, 18: vi113-vi113. DOI: 10.1093/neuonc/now212.471.Peer-Reviewed Original ResearchProgression-free survivalOverall survivalOligodendroglial tumorsBetter progression-free survivalShorter progression-free survivalGroup of patientsSignificant differencesCommon molecular testsFree survivalFavorable prognosisEarly recurrenceShorter survivalPrognostic significancePrognostic valueAnaplastic oligodendrogliomaBrain tumorsTumorsEntire groupMolecular testsCytogenetic patternDeletion statusHallmark featureSurvivalPatientsPolysomyPost-traumatic Stress Disorder and Cardiovascular Disease
Burg MM, Soufer R. Post-traumatic Stress Disorder and Cardiovascular Disease. Current Cardiology Reports 2016, 18: 94. PMID: 27566327, DOI: 10.1007/s11886-016-0770-5.Peer-Reviewed Original ResearchConceptsPost-traumatic stress disorderCardiovascular diseaseStress disorderIncident hypertension riskIncident cardiovascular diseaseAcute cardiac eventsEmergency department environmentCardiac eventsCardiovascular mortalityEarly recurrenceMilitary veteran sampleHypertension riskClinical pathwayPatient experiencePTSD treatmentPTSD onsetTrauma exposureVeteran sampleAutomobile accidentsDepartment environmentMortalityDiseaseRiskTraumaDisordersEarly recurrence of proliferative glomerulonephritis with monoclonal immunoglobulin deposits in a renal allograft
Tewari R, Joshi K, Kumar A, Rayat C, Iyer R, Sakhuja V, Minz M. Early recurrence of proliferative glomerulonephritis with monoclonal immunoglobulin deposits in a renal allograft. Saudi Journal Of Kidney Diseases And Transplantation 2016, 27: 381-385. PMID: 26997395, DOI: 10.4103/1319-2442.178568.Peer-Reviewed Original ResearchMeSH KeywordsAllograftsAntibodies, MonoclonalBiomarkersBiopsyFluorescent Antibody TechniqueGlomerulonephritis, MembranoproliferativeHematopoietic Stem Cell TransplantationHumansImmunoglobulin kappa-ChainsKidneyKidney TransplantationMaleMiddle AgedMultiple MyelomaRecurrenceTime FactorsTreatment OutcomeConceptsMonoclonal immunoglobulin depositsRenal allograftsProliferative glomerulonephritisImmunoglobulin depositsKappa light chain restrictionMembranoproliferative pattern of injuryDeterioration of renal functionAcute graft dysfunctionLight chain restrictionClinico-pathological entityPosttransplant settingChain restrictionEarly recurrenceGraft dysfunctionMembranoproliferative patternRenal biopsyRenal functionRenal transplantationMultiple myelomaDifferential diagnosisMembranoproliferative glomerulonephritisPatterns of injuryGlomerulonephritisRecurrencePGNMID
2014
Correlates and Prognosis of Early Recurrence After Catheter Ablation for Ventricular Tachycardia due to Structural Heart Disease
Nagashima K, Choi EK, Tedrow UB, Koplan BA, Michaud GF, John RM, Epstein LM, Tokuda M, Inada K, Kumar S, Lin KY, Barbhaiya CR, Chinitz JS, Enriquez AD, Helmbold AF, Stevenson WG. Correlates and Prognosis of Early Recurrence After Catheter Ablation for Ventricular Tachycardia due to Structural Heart Disease. Circulation Arrhythmia And Electrophysiology 2014, 7: 883-888. PMID: 25136076, DOI: 10.1161/circep.114.001461.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnti-Arrhythmia AgentsCatheter AblationChi-Square DistributionFemaleHeart DiseasesHumansKaplan-Meier EstimateLogistic ModelsMaleMiddle AgedMultivariate AnalysisOdds RatioProportional Hazards ModelsRecurrenceRetrospective StudiesRisk FactorsTachycardia, VentricularTime FactorsTreatment OutcomeConceptsStructural heart diseaseEarly VT recurrenceVentricular tachycardiaEarly recurrenceHeart diseaseVT recurrenceCatheter ablationNew York Heart Association classificationSustained monomorphic ventricular tachycardiaFirst radiofrequency ablationOptimal treatment strategyHigh-risk groupInduced ventricular tachycardiaMonomorphic ventricular tachycardiaVT stormClinical profileMultivariable analysisPrognostic significancePatient groupIndependent correlatesAssociation classificationRadiofrequency ablationRisk groupsTreatment strategiesAcute failure
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply